Advancing Oxidative
Stress Technology




OXIS INTERNATIONAL, INC.
Rodman and Renshaw, LLC
Global Investment Conference

L...
Advancing Oxidative
  SAFE HARBOR STATEMENT                                                                               ...
Then and Now
Advancing Oxidative
OXIS: FEBRUARY 2009                                                                              Stres...
Advancing Oxidative
OXIS RECENT MILESTONE ACHIEVEMENTS                                                                    ...
Advancing Oxidative
OXIS TODAY                                                                                        Stre...
OXIS ADDRESSES TWO MAJOR HEALTH ISSUES:                                                            Advancing Oxidative
OXI...
Advancing Oxidative
 …WITH VERY LARGE MARKETS                                                                             ...
Scientific Background
OXIDATIVE STRESS: CREATED WHEN FREE RADICALS                                                         Advancing Oxidative
E...
FREE RADICALS CAN CAUSE A VARIETY OF                                                                         Advancing Oxi...
Advancing Oxidative
OXIDATIVE STRESS                                                                                      ...
Advancing Oxidative
VULNERABLE BODY ELEMENTS/DISEASES                                                                 Stre...
Advancing Oxidative
ANTIOXIDANT DEFENSE SYSTEMS                                                                      Stres...
ERGOTHIONEINE (“ERGO”):                                                                                      Advancing Oxi...
ERGO: A MULTI-FACETED,                                                                                                    ...
Consumer Products
Advancing Oxidative
CONSUMER PRODUCTS – TARGET SEGMENTS                                                          Stress Te...
Advancing Oxidative
GO TO MARKET STRATEGIES – NUTRACEUTICALS                                                              ...
GO TO MARKET STRATEGIES –                                                                        Advancing Oxidative
PERSO...
Therapeutic and Clinical Products
THERAPEUTIC AND CLINICAL PRODUCTS –                                                                Advancing Oxidative
HIG...
OXIS THERAPEUTIC AND CLINICAL PRODUCTS –                                                       Advancing Oxidative
IP PORT...
THERAPEUTIC AND CLINICAL PRODUCTS –                                                                Advancing Oxidative
FDA...
Management and Scientific Advisory Board
Advancing Oxidative
MANAGEMENT TEAM                                                                                       ...
Advancing Oxidative
SCIENTIFIC ADVISORY BOARD                                                                          Str...
Advancing Oxidative
INITIAL MEMBERS OF SAB                                                                                ...
Summary
Advancing Oxidative
 MARKET SNAPSHOT (April 30, 2010)                                                                     ...
Advancing Oxidative
 KEY POINTS                                                                                           ...
Thank You
Upcoming SlideShare
Loading in …5
×

Oxis Rodman & Renshaw Presentation

1,070 views

Published on

OXIS International senior management presented on Tuesday, May 18th at 2:50pm BST at the Rodman & Renshaw Annual Global Investment Conference. Chairman & CEO Tony Cataldo and President Bernie Landes unveiled the commercialization and rollout plan of OXIS' powerful patent and IP portfolio.

Published in: Economy & Finance, Business
  • Be the first to comment

  • Be the first to like this

Oxis Rodman & Renshaw Presentation

  1. 1. Advancing Oxidative Stress Technology OXIS INTERNATIONAL, INC. Rodman and Renshaw, LLC Global Investment Conference London, UK // May 16–18, 2010
  2. 2. Advancing Oxidative SAFE HARBOR STATEMENT Stress Technology Except for the historical information contained herein, the matters discussed in this presentation include forward looking statements. Such statements in this presentation, including future financings necessary for operations or acquisitions and future product launch dates are only predictions and reflect current beliefs and expectations of the Company. Actual results may differ materially from those predicted in such forward looking statements due to the risks and uncertainties inherent in the Company’s business, including, without limitation, risk and uncertainties in the obtaining possibly required regulatory approvals, market acceptance of and continuing demand for the Company’s products, the impact of competitive products and pricing and the Company’s ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company’s Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. The Company undertakes no obligation to revise or update this presentation to reflect circumstances after the date hereof. THERAPEUTIC AND MANAGEMENT AND Rodman and Renshaw, LLC | Global Investment Conference THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 1 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  3. 3. Then and Now
  4. 4. Advancing Oxidative OXIS: FEBRUARY 2009 Stress Technology • Pink Sheet Company ―Equity marketcap 3/31/09 = $1.9 Million ―60,000 average daily trading volume (US and Europe) • No cash, many cash liabilities • Limited management and Corporate Board, no functioning science committee • Unable to meet SEC filing requirements • No developed products • No complete strategic plan THERAPEUTIC AND MANAGEMENT AND THEN AND NOW THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 3 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  5. 5. Advancing Oxidative OXIS RECENT MILESTONE ACHIEVEMENTS Stress Technology • Management • Financial Status ― Anthony Cataldo appointed Chairman & CEO ― $2 million capital raised in October 2009 ― Bernie Landes appointed President ― Current liabilities and ongoing expenses at ― New CFO & Corporate Secretary manageable levels ― Additional members with strong experience in marketing and distribution being recruited • Products ― Two nutraceutical products set to launch in summer • Board of Directors - Revitalized with new members 2010 (Many more in pipeline) and functioning committees ― Re-certifying FDA approved drug for veterinary medicine • Scientific Advisory Board Created (With world class recognized experts) • SEC Filings – Up-to-date and complete • Stock Trading ― Equity market cap 3/31/10= $13.7 Million ― Oxis.OB, OXI.PA ― Average daily trading volume over 1,500,000 shares per day (US and Europe) THERAPEUTIC AND MANAGEMENT AND THEN AND NOW THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 4 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  6. 6. Advancing Oxidative OXIS TODAY Stress Technology • Focusing on research, development and sale of products to combat oxidative stress – common abnormality in which free radicals overwhelm antioxidant and other bodily defenses and likely contribute to disease and aging • Building on an estimated $75 million previously invested in IP development • Developing multiple natural substance based products for substantial markets: ― Nutraceuticals ― Personal Care (including Cosmeceuticals) ― Animal Health (drugs and supplements) ― Therapeutic Compounds • Emphasizing L-Ergothioneine (“ERGO”), a highly potent, patent protected, multifaceted antioxidant • Leveraging multiple intellectual property holdings including: 12 patents and 7 patents pending in oxidative stress technologies – continue to build IP with help of SAB • Anticipating growth internally, through mergers and acquisitions, and in/out-licensing THERAPEUTIC AND MANAGEMENT AND THEN AND NOW THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 5 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  7. 7. OXIS ADDRESSES TWO MAJOR HEALTH ISSUES: Advancing Oxidative OXIDATIVE STRESS AND INFLAMMATION Stress Technology • Heart health (Inflammation in arteries) • Brain health (Decline in cognitive ability, Alzheimer’s) • Resistance against diseases (Maintain physiological homeostasis) • Anti-aging/skin care (e.g., Skin protection/rejuvenation) • Inflammation (Arthritis, joint pain) • Detoxification (Liver) • Blood sugar regulation (Protection against developing diabetes) THERAPEUTIC AND MANAGEMENT AND THEN AND NOW THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 6 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  8. 8. Advancing Oxidative …WITH VERY LARGE MARKETS Stress Technology OXIS CONSUMER PRODUCTS* • Dietary supplements: $25 billion • Functional foods and beverages: $37 billion • Personal care (including cosmetics): $10 billion • Companion animal supplements: $17 billion OXIS THERAPEUTIC/CLINICAL PRODUCTS • Veterinary health: $11 billion** • Pharmaceutical compounds for target indications – several exceeding $100 million in size *=Market size estimates for 2008 by Nutritional Business Journal **=Market size estimate for 2008 by Vetnosis, Ltd. THERAPEUTIC AND MANAGEMENT AND THEN AND NOW THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 7 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  9. 9. Scientific Background
  10. 10. OXIDATIVE STRESS: CREATED WHEN FREE RADICALS Advancing Oxidative EXCEED BODY’S NATURAL DEFENSES Stress Technology FREE RADICALS • An atom or group of atoms with unpaired electrons, creating Normal unstable situations where cells and important organs may Oxygen Atom be damaged • Generated normally as result of naturally occurring processes when the body’s cells use oxygen to produce energy Loss of Electron • Also result from other sources: air pollution, tobacco smoke, ultraviolet rays, agricultural chemicals, psychological stress, exhaustive exercise, drug intake and inflammation Free • Increases with aging and disease Radical THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 9 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  11. 11. FREE RADICALS CAN CAUSE A VARIETY OF Advancing Oxidative DESTRUCTIVE ACTIONS ON CELLS Stress Technology Nucleus Oxygen Chromosome Glucose Oxygen radical with unpaired electron Superoxide dismutase Energy Damage to mitochondrial DNA Hydrogen Peroxide Motor Neuron Catalase Damage to Oxygen Nuclear DNA Water THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 10 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  12. 12. Advancing Oxidative OXIDATIVE STRESS Stress Technology • Created by an imbalance in the physiologic ability (natural and ingested antioxidants) to combat free radicals • May be accelerated by excess alcohol and certain foods, certain pharmaceutical drugs, strenuous exercise, inflammation and aging process Disease Good Health Disease Good Health Free Radicals Antioxidants Free Radicals Antioxidants THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 11 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  13. 13. Advancing Oxidative VULNERABLE BODY ELEMENTS/DISEASES Stress Technology • Brain (Protein damage: Parkinson, Alzheimer, ALS) • Eye (Cataract) • Skin (Protein damage; Pre-Mature Aging) • Heart (Lipid damage: Atherosclerosis) • Lungs (Emphysema, COPD) • Cancer (DNA damage) • Reproductive System (Sperm protection) • Various Inflammation Related (Arthritis) THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 12 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  14. 14. Advancing Oxidative ANTIOXIDANT DEFENSE SYSTEMS Stress Technology • Internally produced antioxidant enzymes ―Superoxide dismutase (SOD) ―Catalase ―Glutathione Peroxidase (GPx) • Ingested in diet and supplements: ―Vitamin A, C, E, beta-carotenes ―Proanthocyanins, anthocyanins, polyphenols, flavonoids, and metal chelators • However, natural antioxidant systems can be overwhelmed creating Oxidative Stress leading to disease states and premature aging THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 13 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  15. 15. ERGOTHIONEINE (“ERGO”): Advancing Oxidative PROPRIETARY SCIENCE BASE FOR INITIAL PRODUCTS Stress Technology • Highly potent naturally occurring multifaceted • Significant well-documented benefits of ERGO antioxidant - can’t be made internally by humans (based on over 100 research papers and studies): ― Conserves other antioxidants- • Humans have special transporter system to Vitamin E and Glutathione (GSH) concentrate ERGO in specific locations as needed ― Increases respiration and oxidation of fat ― Reduces damage from ultraviolet radiation • Found naturally in certain mushrooms, grapes, ― Protects mitochondria from damage other foods, but not in quantities that can be ingested in sufficient amounts to help humans ― Directly scavenges certain free radicals and oxidants • OXIS has proprietary technology to make ERGO ― Protects against damage from in sufficient strength to be a dietary supplement neuro-toxins that maybe responsible for and food/beverage ingredient creating cognitive decline • Oxis has 3 patents and 2 patent pending ― Protects red blood cells applications for ERGO (Several more in development) THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 14 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  16. 16. ERGO: A MULTI-FACETED, Advancing Oxidative ANTI-INFLAMMATORY ANTIOXIDANT Stress Technology Potential ERGOTHIONEINE Pharmacogenomic Benefit Direct Antioxidant Scavenging Action Indirect Antioxidant Stimulation of Antioxidant Enzymes (GPx, GRx) Genetic and Epigenetic Regulator ROS Antiox Antioxidant Anti-Inflammatory Aging Inflammation OXIDATIVE STRESS Infection Cancer Neurodegenerative Alzheimer’s Diabetes, Atherosclerosis, Metabolic Diseases Diseases Parkinson’s Cardiovascular diseases THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 15 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  17. 17. Consumer Products
  18. 18. Advancing Oxidative CONSUMER PRODUCTS – TARGET SEGMENTS Stress Technology NUTRITION AND WELLNESS • Dietary Supplements • Functional Foods • Functional Beverages (e.g., energy drinks) PERSONAL CARE • Creams • Cosmetics • Hair care THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS CONSUMER PRODUCTS 17 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  19. 19. Advancing Oxidative GO TO MARKET STRATEGIES – NUTRACEUTICALS Stress Technology • Build direct to consumer sales relationships • Two product launches for Summer 2010 to maximize margins and repeat sales (Others to follow shortly afterwards) ―“Ergo-Pure” - ERGO in pure • Create marketing alliances with key thought leaders by product category form as a highly potent multifaceted antioxidant • Establish multiple channels: ―“Ergo-Plex” – ERGO plus other functional ―Multi-level marketing nutraceutical ingredients directed at Joint ―Internet sales Health/Pain relief. ―TV Infomercials • Actively exploring several joint venture and ―Long and short form radio infomercials acquisition opportunities ―Direct mail ―Traditional retail approaches THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS CONSUMER PRODUCTS 18 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  20. 20. GO TO MARKET STRATEGIES – Advancing Oxidative PERSONAL CARE PRODUCTS Stress Technology • Develop line of ERGO based products with mass marketer (Walmart, Walgreens, CVS, etc.) • Develop line of products independently – go to market via direct mail, Internet, infomercials or combination • Develop strategic partnership with spa market participants and promote custom developed products • Develop separate line of personal care products for dermatology market and then also sell at upscale retail channels such as Bloomingdales and Sephora THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS CONSUMER PRODUCTS 19 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  21. 21. Therapeutic and Clinical Products
  22. 22. THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative HIGH UPSIDE POTENTIAL Stress Technology • Oxis has 9 patents and 5 patent pending applications that cover a number of current and potential therapeutic and clinical applications • Most indications for still available for out-licensing to biotech and pharmaceutical companies • Anti-inflammatory indications seem most promising • Several ERGO analogs (antioxidant mimics and variations of ERGO) also may have promise in neurodegenerative (Alzheimer’s and Parkinson’s), diabetes and cardiovascular diseases GAME PLAN: • Initiate out-license program • Add to IP based on relationships with leading researchers as guided by SAB • JVs with third parties (Several under consideration) THERAPEUTIC AND THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 21 CLINICAL PRODUCTS CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  23. 23. OXIS THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative IP PORTFOLIO HIGHLIGHTS Stress Technology BXT-51072 ―Action: Low weight anti-inflammatory glutathione peroxidase mimicking molecule that metabolizes lipid peroxides ―Target Indications: cardiovascular and inflammatory bowel diseases LIPID SOLUBLE ANTIOXIDANT COMPOUNDS ―Action: Natural cell penetrating potent (20-40X) agent that mimics Vitamin E ―Target Indications: neurodegenerative (Alzheimer’s and Parkinson’s) and cardiovascular diseases SUPEROXIDE DISMUTASE (“SOD”) RELATED COMPOUNDS ―Action: Naturally occurring ubiquitous enzyme that reduces superoxide (a pivotal free radical) found in all living organisms ―Target Indications: Inflammatory joint disease and prevention of radiation toxicity THERAPEUTIC AND THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 22 CLINICAL PRODUCTS CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  24. 24. THERAPEUTIC AND CLINICAL PRODUCTS – Advancing Oxidative FDA APPROVED DRUG FOR ANIMALS Stress Technology • Palosein™ - anti-inflammatory form of SOD (Orgotein) • Derived from bovine liver • Previously sold by Oxis • Currently re-certifying manufacturing process to resume sales • In discussions with potential distribution partners THERAPEUTIC AND THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 23 CLINICAL PRODUCTS CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  25. 25. Management and Scientific Advisory Board
  26. 26. Advancing Oxidative MANAGEMENT TEAM Stress Technology ANTHONY CATALDO • Overall management, financings, investor and public relations CHAIRMAN & CEO, • Multiple times public company CEO or Chairman with life science focus (Calypte, Senetek) DIRECTOR • Significant public company investor relations and financing experience • Overall product/market strategy, mergers, acquisitions, alliances nutraceutical and cosmeceutical product development and management BERNIE LANDES PRESIDENT • Multiple top management and advisory roles in nutrition, natural foods, supplements, skin care • Experience at Suracell, Monavie, Zila, Paracelsian, Alacer, Health Valley • Overall responsibility for financial management and reporting MICHAEL HANDELMAN CFO & TREASURER • Multiple times CFO including LA Kings Hockey Team and several start-ups • CPA • Corporate Governance, Administration, Special Projects GARY POST SECRETARY & • Multiple interim public and private company Board Member/CEO/COO – initiated Oxis strategy transition DIRECTOR • Investing and advising with Ambient Advisors, McKinsey, Kidder Peabody, Drexel Burnham THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 25 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD SCIENTIFIC ADVISORY BOARD
  27. 27. Advancing Oxidative SCIENTIFIC ADVISORY BOARD Stress Technology A STRONG SAB IS ACTIVELY ASSISTING WITH KEY CONTRIBUTIONS: • Participating in product development • Evaluating and contributing to additional IP opportunities • Evaluating merger, in and out-license opportunities • Assisting in communicating the Oxis science story to investors THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 26 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD SCIENTIFIC ADVISORY BOARD
  28. 28. Advancing Oxidative INITIAL MEMBERS OF SAB Stress Technology OKEZIE I. AROUMA, JOHN E. REPINE, M.D. BSc, MBA, PhD, MSc, DSc • Waring Professor of Medicine, Pediatrics • Professor of Pharmaceutical and Surgery at University of Colorado and Biomedical Sciences, and Director of Webb-Waring Center Touro College of Pharmacy, NYC • Pulmonary/Critical Care Specialist • Biochemist, world expert and and expert in antioxidant and leading researcher re: Ergothioneine inflammatory research and Oxidative Stress • Author of over 300 peer review articles • Author of 10 books and 250 peer review and 14 patent applications papers focused on oxidative stress, dietary antioxidants and diseases of overt inflammation, two patent applications Other candidates under consideration for the SAB have complementary specialties in science and product development THERAPEUTIC AND MANAGEMENT AND THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS 27 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD SCIENTIFIC ADVISORY BOARD
  29. 29. Summary
  30. 30. Advancing Oxidative MARKET SNAPSHOT (April 30, 2010) Stress Technology COMMON STOCK TICKER: (OXIS.OB) (OXI.PA) STOCK PRICE: $0.19 52 WEEK RANGE: $0.04 – $0.61 SHARES OUTSTANDING: 102.5 million MARKET CAPITALIZATION: $ 19.5 million THERAPEUTIC AND MANAGEMENT AND Rodman and Renshaw, LLC | Global Investment Conference THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 29 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  31. 31. Advancing Oxidative KEY POINTS Stress Technology • Large potential markets for unique products, especially incorporating ERGO • Strong IP position • Diversified strategies for growth • Highly qualified Management and SAB team THERAPEUTIC AND MANAGEMENT AND MANAGEMENT AND Rodman and Renshaw, LLC | Global Investment Conference THEN AND NOW SCIENTIFIC BACKGROUND CONSUMER PRODUCTS May 2010 30 CLINICAL PRODUCTS SCIENTIFIC ADVISORY BOARD
  32. 32. Thank You

×